Lexaria Bioscience FY IP Licensing Revenue Rises to USD 0.7 Million, Up 52%
I'm PortAI, I can summarize articles.
Lexaria Bioscience Corp. reported a net loss of USD 11.9 million for the year ending August 31, 2025, compared to USD 5.8 million the previous year. IP Licensing revenue increased by 52% to USD 0.7 million. However, the company expressed concerns about its ability to meet operational requirements over the next year due to insufficient cash and anticipated inflows. Since entering the bioscience sector, Lexaria has accumulated net losses of USD 63.5 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments